Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Mavorixafor has demonstrated significant short-term efficacy in raising neutrophil counts and reducing infections in controlled trials. In the pivotal Phase 3 trial for WHIM syndrome, mavorixafor significantly increased patients’ neutrophil levels above the severe neutropenia threshold compared to placebo, translating into clinical benefit with a 60% reduction in infection rates. However, there is no direct head-to-head trial data against the standard of care (G-CSF), which limits the ability to definitively claim superiority.
Cost effectiveness
Mavorixafor is a high-cost orphan drug with an annual cost of approximately £496,400. There is no published cost-effectiveness analysis or incremental cost-effectiveness ratio (ICER) available, making it impossible to assess its economic value. The absence of utility values and formal economic evaluations indicates a significant gap in the evidence base.
Quality of life
Validated quality of life instruments such as EQ-5D or SF-36 have not been prominently reported in the clinical studies of mavorixafor. The trials collected some patient-reported outcomes, but mostly via global impression scales rather than comprehensive QoL questionnaires. This indicates a lack of robust evidence on HRQoL improvements, despite anecdotal reports suggesting potential benefits.
Supporting Domains
Safety and Adverse Effects
Mavorixafor has demonstrated a favorable short-term safety profile with no treatment-related serious adverse events reported in clinical trials. Common adverse events were mostly mild, indicating good tolerability. The long-term safety data are still limited, but no significant safety concerns have emerged thus far.
Comparator Selection
The comparators used in mavorixafor trials reflect the reality that the standard of care for chronic neutropenia is either G-CSF or nothing. The trial design allowed patients to continue their usual therapy, ensuring that the evidence generated is directly applicable to real-world practice.
Patient Population and Subgroups
The trials included key subtypes of chronic neutropenia, making the study population representative of the intended real-world patient population. However, children under 12 were excluded, which leaves a gap in the evidence for that subgroup.
Care Pathway Integration
Mavorixafor can be integrated into existing healthcare delivery pathways without requiring new infrastructure or training. The drug’s oral administration simplifies the treatment process compared to G-CSF injections, which is a positive aspect for patient management.
Resource Use and Cost Implications
The introduction of mavorixafor will significantly increase direct medical costs due to its high price. While some cost savings may arise from reduced hospitalizations and G-CSF usage, these are unlikely to offset the drug’s cost, leading to a substantial budget impact.
Evidence Quality and Robustness
The evidence for mavorixafor comes from well-controlled Phase 3 trials, demonstrating high methodological rigor. However, the small sample sizes and reliance on a single pivotal trial raise some concerns about the robustness of the findings.
Uncertainty, Sensitivity, and Broader Impacts
There are several uncertainties regarding long-term efficacy, safety, and cost-effectiveness. While the clinical evidence is strong, the lack of long-term data and economic evaluations introduces significant uncertainty for decision-makers.
